National Survey on Dyslipidemic Patients - Full Text View

National Survey on Dyslipidemic Patients (PRYSME)

This study is currently recruiting participants.

Verified by AstraZeneca, June 2008

Sponsored by:	AstraZeneca
Information provided by:	AstraZeneca
ClinicalTrials.gov Identifier:	NCT00701402

Purpose

The purpose of this observational study is to describe the time to lipid-lowering drug implementation in the management of dyslipidemic patients, according to the cardiovascular risk level.

Condition
Dyslipidemia

Drug Information available for: Lipids

U.S. FDA Resources

Study Type:	Observational
Study Design:	Cohort, Cross-Sectional
Official Title:	Survey on Time to Lipid-Lowering Drug Implementation on Dyslipidemic Patients in General Practice.

Further study details as provided by AstraZeneca:

Primary Outcome Measures:

time to lipid-lowering drug implementation (immediately, treatment within a period 0-3 month and > 3 month, according to the cardiovascular risk level, (0 risk factor, 1 risk factor, 2 risk factors, ≥ 3 risk factors, secondary prevention). [ Time Frame: Once ] [ Designated as safety issue: No ]

Biospecimen Retention: None Retained

Biospecimen Description:

Estimated Enrollment:	4500
Study Start Date:	June 2008
Estimated Study Completion Date:	October 2008

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No
Sampling Method:	Probability Sample

Study Population

First three consecutive dyslipidemic patients seen by GP

Criteria

Inclusion Criteria:

Diagnosis of dyslipemia made less than 2 years
Treated by a lipid-lowering drug
Agree to take part in the survey

Exclusion Criteria:

Patient included in a clinical trial

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00701402

Contacts

Contact: AstraZeneca France Clinical Study Information

01 41 29 40 00

stephan.becouarn@astrazeneca.com

Show 1207 Study Locations

Sponsors and Collaborators

AstraZeneca

Investigators

Study Director:

Alain Castaigne

AstraZeneca

More Information

Responsible Party:	AstraZeneca Pharmaceuticals ( Alain Castaigne, Medical Director )
Study ID Numbers:	NIS-CFR-DUM-2007/9
Study First Received:	June 18, 2008
Last Updated:	June 19, 2008
ClinicalTrials.gov Identifier:	NCT00701402
Health Authority:	France: French Data Protection Authority

Keywords provided by AstraZeneca:

time to lipid-lowering drug implementation
dyslipidemic patients

Study placed in the following topic categories:

Metabolic Diseases
Metabolic disorder
Dyslipidemias
Lipid Metabolism Disorders

ClinicalTrials.gov processed this record on January 16, 2009